Drugs / ASP9801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03954067 | Sep 2019 → Apr 2024 | metastatic malignant neoplasm | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP9801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03954067 ↗ |
| Modality | Other / unclassified | “ASP9801, an Oncolytic Virus” NCT03954067 ↗ |
| Route | Other | “Administered by intratumoral injection” NCT03954067 ↗ |